Cargando…
In Vitro and In Vivo Characterization of a Fully Felinized Therapeutic Anti‐Nerve Growth Factor Monoclonal Antibody for the Treatment of Pain in Cats
BACKGROUND: Limited options are available for the treatment of pain in cats. Monoclonal antibodies (mAbs) that neutralize nerve growth factor (NGF) have demonstrated analgesic capacity in rodent models, people with osteoarthritis, and dogs with degenerative joint disease. HYPOTHESIS/OBJECTIVES: This...
Autores principales: | Gearing, D.P., Huebner, M., Virtue, E.R., Knight, K., Hansen, P., Lascelles, B.D.X., Gearing, R.P., Drew, A.C. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5094543/ https://www.ncbi.nlm.nih.gov/pubmed/27306920 http://dx.doi.org/10.1111/jvim.13985 |
Ejemplares similares
-
A Feline‐Specific Anti‐Nerve Growth Factor Antibody Improves Mobility in Cats with Degenerative Joint Disease–Associated Pain: A Pilot Proof of Concept Study
por: Gruen, M.E., et al.
Publicado: (2016) -
Frunevetmab, a felinized anti‐nerve growth factor monoclonal antibody, for the treatment of pain from osteoarthritis in cats
por: Gruen, Margaret E., et al.
Publicado: (2021) -
A fully caninised anti-NGF monoclonal antibody for pain relief in dogs
por: Gearing, David P, et al.
Publicado: (2013) -
Questionnaire‐based Analysis of Owner‐reported Scratching and Pain Signs in Cavalier King Charles Spaniels Screened for Chiari‐like Malformation and Syringomyelia
por: Sparks, C.R., et al.
Publicado: (2017) -
Association of Canine Osteosarcoma and Monocyte Phenotype and Chemotactic Function
por: Tuohy, J.L., et al.
Publicado: (2016)